Jan 09, 2023 / 05:45PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm a large cap biotech analyst at JPMorgan. Delighted to be continuing the conference this morning with Alnylam, driven by a number of members of the company's management team up on stage. And just as a housekeeping note, we don't have to switch room for Q&A this year. We're going to stay in this room. There's going to be mic runners if you want to raise your hand and ask a question. If you don't want to do it the old fashion, then you can also enter a question electronically on the portal and I can read it off the iPad out here or you can listen to my question if you don't want to ask your own. But with that, I will pass it over to the company's CEO, Yvonne Greenstreet, for the presentation.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
Thanks, Jessica. I have to say it's wonderful to be here in person to give us an opportunity to share an update on our progress at Alnylam. And I'm delighted to be
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers